How many stocks are there of Beigene?
The current number of stocks of Beigene is 1.36 B undefined.
Beigene Stocks 2024
Beigene Stocks
1.36 B
Ticker
6160.HK
ISIN
KYG1146Y1017
WKN
A144EN
In 2024, Beigene had 1.36 B outstanding stocks, a 0% change from the 1.36 B stocks in the previous year.
The Beigene Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 1.36 |
| 2028e | 1.36 |
| 2027e | 1.36 |
| 2026e | 1.36 |
| 2025e | 1.36 |
| 2024e | 1.36 |
| 2023 | 1.36 |
| 2022 | 1.34 |
| 2021 | 1.33 |
| 2020 | 1.33 |
| 2019 | 1.33 |
| 2018 | 1.33 |
Beigene shares outstanding KYG1146Y1017 · A144EN
The number of shares was Beigene in 2023 — This indicates how many shares 1.357 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Beigene earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Beigene's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Beigene’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Beigene's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2018 | 1.33 B Aktien |
| 2019 | 1.33 B Aktien |
| 2020 | 1.33 B Aktien |
| 2021 | 1.33 B Aktien |
| 2022 | 1.34 B Aktien |
| 2023 | 1.36 B Aktien |
| 2024e | 1.36 B Aktien |
| 2025e | 1.36 B Aktien |
| 2026e | 1.36 B Aktien |
| 2027e | 1.36 B Aktien |
| 2028e | 1.36 B Aktien |
| 2029e | 1.36 B Aktien |
Beigene Aktienanalyse
What does Beigene do?
Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Beigene's Shares Outstanding
Beigene's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Beigene’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Beigene’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Beigene’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Beigene stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Beigene are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Beigene evolved in recent years?
The number of shares of Beigene has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Beigene as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Beigene?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Beigene pay?
Over the past 12 months, Beigene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beigene is expected to pay a dividend of 0 USD.
What is the dividend yield of Beigene?
The current dividend yield of Beigene is .
When does Beigene pay dividends?
Beigene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Beigene?
Beigene paid dividends every year for the past 0 years.
What is the dividend of Beigene?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Beigene located?
Beigene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Beigene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Beigene from 9/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/15/2024.
When did Beigene pay the last dividend?
The last dividend was paid out on 9/15/2024.
What was the dividend of Beigene in the year 2023?
In the year 2023, Beigene distributed 0 USD as dividends.
In which currency does Beigene pay out the dividend?
The dividends of Beigene are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Beigene
Our stock analysis for Beigene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beigene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
